Update on the management of patients with intermediate and poor-risk testicular germ cell tumors and new biological insights [0.03%]
睾丸精原细胞瘤中危与高危患者管理的更新及新的生物学见解
Antonio Mérida-García,Asunción Díaz-Serrano,Brandon Bernard et al.
Antonio Mérida-García et al.
Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer [0.03%]
序贯放疗和sipuleucel-T单药治疗转移性去势抵抗性前列腺癌患者的II期随机试验
Przemyslaw Twardowski,Jeffrey Y C Wong,Sumanta K Pal et al.
Przemyslaw Twardowski et al.
Background: Sipuleucel-T is an autologous cellular immunotherapy indicated for patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer (mCRPC). Since radiation therapy (RT) can ...
Impact of timing of administration of bone supportive therapy on pain palliation from radium-223 [0.03%]
骨改良药物的用药时间对其用于配合 radium-223 治疗骨痛的影响研究
Kelly Khai-Li Yap,William Wong,Lingyun Ji et al.
Kelly Khai-Li Yap et al.
Background: Skeletal-related events cause significant morbidity in patients with metastatic castration-resistant prostate cancer. In the ALSYMPCA study, radium-223 (Ra223) was found to provide pain palliation in addition ...
First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer [0.03%]
用于表皮生长因子受体突变阳性及MET阳性非小细胞肺癌患者的一线onartuzumab联合厄洛替尼治疗
Kazuma Kishi,Hiroshi Sakai,Takashi Seto et al.
Kazuma Kishi et al.
Introduction: The phase II JO28638 study evaluated first-line onartuzumab plus erlotinib in patients with MET-positive advanced, metastatic, or post-operative recurrent non-small-cell lung cancer (NSCLC) with epidermal gr...
Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients [0.03%]
阿比特龙治疗转移性去势抵抗性前列腺癌：未选择患者的疗效和安全性分析
Grégoire Marret,Ludovic Doucet,Christophe Hennequin et al.
Grégoire Marret et al.
Background: Abiraterone acetate (AA), an androgen biosynthesis inhibitor, is now a standard of care for men with metastatic, castration-sensitive and castration-resistant prostate cancer (mCRPC). Data exploring real-world...
Comparative Study
Cancer treatment and research communications. 2018:17:37-42. DOI:10.1016/j.ctarc.2018.10.001 2018
Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study [0.03%]
量化感觉检测在奥沙利铂神经病变管理中的作用：两年临床研究
J B Delmotte,H Beaussier,N Auzeil et al.
J B Delmotte et al.
Purpose: To better understand how quantitative sensory testing could help the clinician in the management of oxaliplatin-induced peripheral neuropathy in terms of earlier and more reliable detection, we conducted a two-ye...
Systematic review and two new cases of primary upper urinary tract neuroendocrine carcinomas [0.03%]
原发上尿路神经内分泌癌的系统回顾及两例新报告
Takehiko Nakasato,Aya Hiramatsu,Yuki Matsui et al.
Takehiko Nakasato et al.
Background: Upper urinary tract neuroendocrine carcinoma (UUT-NEC) is extremely rare and has a poor prognosis. Although a few cases of successful treatment have been reported, no treatment has shown established efficacy. ...
Prognostic value of total lesion glycolysis and metabolic active tumor volume in non-small cell lung cancer [0.03%]
总糖酵解和代谢活跃肿瘤体积在非小细胞肺癌中的预后价值分析
Karolien Vanhove,Liesbet Mesotten,Micheline Heylen et al.
Karolien Vanhove et al.
Introduction: To predict the outcome of patients with non-small cell lung cancer (NSCLC) the currently used prognostic system (TNM) is not accurate enough. The prognostic significance of the SUVmax measured by PET remains...
Audrey Arjomandi,Michelle L Delanoy,Roger P Walker et al.
Audrey Arjomandi et al.
Background: Measurement of autoantibodies (AAbs) to tumor associated antigens has been proposed to aid in the early detection of ovarian cancer with high specificity. Here we describe a multiplex approach to evaluate sele...
Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2 [0.03%]
基于铂的化疗晚期肺腺癌患者的基因组特征分析发现SMYD2基因具有预后价值的遗传变异
Iván Galván-Femenía,Marta Guindo,Xavier Duran et al.
Iván Galván-Femenía et al.
Objective: The aim of the study was to investigate the relationship between germline variations as a prognosis biomarker in patients with advanced Non-Small-Cell-Lung-Cancer (NSCLC) subjected to first-line platinum-based ...